Discover key insights from Biogen's Q1 2025 earnings call, highlighting LEQEMBI's growth, product launches, and a strong pipeline driving ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to Alzheimer's disease.